Regeneron Reports Third Quarter 2018 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Regeneron Reports Third Quarter 2018 Financial and Operating Results
November 7, 2018 7:34 AM EST
Barclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 (from $305.00) while maintaining a Underweight rating following the company's 3Q earnings report.
Meacham thought Regenerons 3Q results were very good (+$22M top-line; +$0.70 bottom-line), and while Barclays continues to... More
November 6, 2018 6:37 AM EST
Regeneron (NASDAQ: REGN) reported Q3 EPS of $5.87, $0.69 better than the analyst estimate of $5.18. Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.64 billion.
Third quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarter 2018 EYLEA global net sales(1) increased 11% to $1.68 billion versus third quarter 2017U.S. launch of Libtayo® (cemiplimab-rwlc) Injection for the...
More
